ExeVir Bio, a spin out of VIB, the leading Belgium-based life sciences research institute, is harnessing its Llama-derived antibody (VHH) technology platform to generate robust antiviral therapies providing broad protection against viruses with a lead candidate for SARS Cov-1&2. To accelerate our lead, UCB, a multinational biopharmaceutical company, assisted in the generation of the lead candidate and is producing the GMP batches for clinical trials. Fund+, a leading EU Life Sciences-focused investment firm in Belgium, led the 1st closing financing, pulling together a strong consortium including UCB Ventures, FPIM, V-Bio and VIB.
ExeVir Bio is using a highly innovative and clinically validated VHH technology to develop treatments for viral infections that may pose a significant global threat. Lead asset VHH72-Fc binds to a unique epitope that is conserved in SARS-CoV-1 and SARS-CoV-2 viruses and this binding prevents these viruses from entering the cell. Its VHH format has particular advantages over convalescent derived antibodies including potential reduced risk of mutant escapes. This approach could be used both as a therapeutic and prophylactic. Therapeutic use could help slow viral replication in the lungs, reduce inflammation, and give patients valuable time to raise their own productive immune response.